We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
GSK Pharmaceuticals Ltd will be buying back 25 percent of equity from its shareholders
at Rs. 800 per share, stated the company's chairman Deepak Parekh at its 80th
annual general meeting held on Wednesday in Mumbai.
Oxford BioMedica, the leading gene therapy company, announces that they have
received a notice of allowance from the U.S. Patent Office for a patent containing
broad claims covering modifications to lentiviral vectors that improve safety
and efficacy.
Strides Arcolab Ltd. said on Wednesday it had struck a five-year contract with
a U.S.-based firm to develop four injectable products for the United States
market in a deal valued at $90-160 million.
NicOx S.A. announced it has received a payment of EUR 1 million from Pfizer
Inc. in connection with the companies' Research, Option, Development and Licensing
agreement that was signed on Aug. 26, 2004.
InKine Pharmaceutical Co. Inc. said it received
a $1 million milestone payment from Zeria Pharmaceutical Co., which is serving
as InKine's licensee for the company's sodium phosphate tablets in Japan.
While the international drug community continues to express its dissatisfaction
at the level of patent protection in Venezuela, it should expect little in the
way of reform in the short term.
Spanish generics makers' association AESEG has reported that the value of the country's generics sector increased by some 19% in 2004, but the market is still only worth EUR410mn (US$530.67mn).
Malaysia's drug market is expected to grow strongly in the next few
years, but government aspirations to attract foreign investment to biotech ventures
and make the sector a key growth driver are unlikely to be fulfilled in the
medium term.